MAP2K7 and melanoma: Accordingly, glembatumumab vedotin, a gpNMB-targeted MMAE-conjugated ADC [69], resulted in a 39% ORR in a phase I/II study conducted among patients with advanced melanoma refractory to ICI and BRAF/MEK inhibition, with acceptable toxicity (NCT00412828) [70].